Trial record 2 of 3 for:
Open Studies | "Herpes Labialis"
Comparison of Topical Antiviral Agents for Labial Cold Sores (Herpes Labialis)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2007 by Hadassah Medical Organization.
Recruitment status was Not yet recruiting
Recruitment status was Not yet recruiting
Sponsor:
Hadassah Medical Organization
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00467662
First received: April 17, 2007
Last updated: April 30, 2007
Last verified: April 2007
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Recurrent cold sores - herpes simplex labialis (HSL) occurs in 20-40% of the US population and patient seek treatment because of the discomfort and visibility of the lesion although it is a self limiting disease. The purpose of this study is to check the safety, Efficacy and convenience of Use of the Natural Agent "Superlysin Gel" as Treatment for Herpes Labialis in Comparison to Acyclovir 5% and Docozanole 10%.
| Condition | Intervention | Phase |
|---|---|---|
|
Reccurent Herpes Labialis |
Drug: Acyclovir 5% Drug: Docosanol 10% Device: Superlysine gel |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Factorial Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | The Safety, Efficacy and Convenience of Use of the Natural Agent "Superlysin Gel" as Treatment for Herpes Labialis in Comparison to Acyclovir 5% and Docozanole 10%. |
Resource links provided by NLM:
Further study details as provided by Hadassah Medical Organization:
Primary Outcome Measures:
- Reducing healing process and duration of cold sores using superlysin gel
| Estimated Enrollment: | 75 |
Study design:
-Double blinded non-inferiority prospective parallel-group, intend to treat trial. Enrolment of 75 patients (25 randomized for each group). - Approval of the Institutional Ethical Review Board -
Study design:
- Patient characteristics (selected) and historical information assessment including: Race, average episode duration from patient history Duration of most recent previous episode Time since last onset of oral-facial herpes simplex Time since first onset of oral-facial herpes simplex Does patient experience localized prodrome?
- Experiment duration; 5 to 10 days
- 4 visits (days 1, 3,6,10)
- 5 application /day for each derivative
- Documentation Metric digital images of localized area signs at each visit Clinical assessment of prodrome/erythema, papule, vesicle, ulcer, crust, or healed skin (with or without residual erythema) Visual analogue scale (VAS) for subjective assessment of pain, burning, itching or tingling at each visit
- Calculation of primary efficacy end point (time to healing); from the date and time of the initiation of therapy until the date and time of the clinic visit at which complete resolution of all local signs and symptoms, i.e. the lesion had aborted or complete healing had occurred (censored at day 10)
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria:
- Signed informed consent
- Age range (yrs) 18-70
- Gender ; Males and females
- Health status; immuno-competent
- Clinical history of HSL with at least two recurrences during the past 12 months. The most recent previous episode must have healed at least 14 days before screening.
- Less than 12 hours after prodrome initiation (i.e. local erythema w/o blistering, tingling and or burning sensation, soreness)
Exclusion criteria:
- Pregnant women
- Mentally disabled
- No intra-oral lesions, or lesions above the nostrils and below the chin
- No topical steroid use and no systemic antiviral current treatments within 7 days before the study
- No known allergies to topical cosmetics
- No use cosmetics on or around the mouth during the treatment period
- No concomitant use of systemic corticosteroids or other drugs known to induce immune stimulation or immune suppression
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00467662
Contacts
| Contact: Doron J Aframian, DMD, PhD | 0097226776151 | Daframian@yahoo.com |
Sponsors and Collaborators
Hadassah Medical Organization
Investigators
| Study Chair: | Doron Aframian, DMD,PhD | Salivary Gland Clinic, Department of Oral Medicine The Hebrew University-Hadassah School of Dental Medicine Jerusalem, Israel P.O.B 12272, Zip code 91120 |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00467662 History of Changes |
| Other Study ID Numbers: | 376.hmo-ctil |
| Study First Received: | April 17, 2007 |
| Last Updated: | April 30, 2007 |
| Health Authority: | Israel: Ministry of Health |
Additional relevant MeSH terms:
|
Herpes Labialis Herpes Simplex Herpesviridae Infections DNA Virus Infections Virus Diseases Skin Diseases, Viral Lip Diseases Mouth Diseases Stomatognathic Diseases |
Skin Diseases, Infectious Skin Diseases Acyclovir Antiviral Agents Docosanol Anti-Infective Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 23, 2013